



Marshfield Labs™

Laboratory News

VOL. 44, NO. 3 – April 26, 2021

Microbiology Lab Updates

Thomas Novicki PhD D(ABMM), Clinical Scientist, Microbiology

Effective date: March 24, 2021

Following discussions with our infectious diseases specialists and the antimicrobial stewardship committee, we will make these changes to the testing and reporting of antimicrobial agents:

INSIDE THIS ISSUE

Microbiology Lab Updates

Changes to testing and reporting of antimicrobial agents..... 1



1. Discontinue routinely reporting ertapenem. This drug will be available upon request to the Microbiology lab.
2. Due to the tendency for the *Citrobacter freundii* complex, *Enterobacter cloacae* complex, *Hafnia alvei* & *Klebsiella (Enterobacter) aerogenes* to develop resistance to ampicillin and 1st – 3rd generation cephalosporins during treatment with these drugs we will do the following for these species:
 - a) Always report ampicillin, amoxicillin/ clavulanic acid, cefazolin, ceftriaxone & ceftazidime as Resistant.
 - b) Add the following comments:
 - i. Blood isolates: “Treatment failures have occurred with use of cefepime and piperacillin/tazobactam. Consultation with an Infectious Diseases specialist is recommended.”
 - ii. Isolates from all other sources: “Treatment failures have occurred with use of cefepime and piperacillin/tazobactam. Repeat cultures in 3-4 days may therefore be warranted.”
3. Return to performing micro-broth dilution antimicrobial susceptibility testing for non-fermenting Gram negative bacilli (e.g. Burkholderia cepacia complex, Stenotrophomonas maltophilia) in-house using micro-broth dilution MIC methodology. (This testing had been temporarily directed to our reference lab due to a technical limitation.)

Please feel free to contact me, an infectious diseases specialist, or Logan Whitfield, Pharm. D. with questions about these changes.